Chemogenomic profiling for blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The project collects retrospective and prospective bone marrow, peripheral blood, lymph node or tissue samples at the University Hospital of Parma and applies genetic, molecular and multi-omics analyses. It includes a broad range of hematological malignancies defined by the WHO 2016 classification, including acute and chronic leukemias, myeloproliferative and lymphoproliferative disorders, and myelodysplastic syndromes. The work seeks to link molecular and chemogenomic signatures with diagnostic categories, relapsed/refractory disease and blastic transformation. Findings are intended to inform more precise diagnosis and to generate hypotheses about potential therapeutic targets.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient aged \>1 year old, referred for evaluation to the University Hospital of Parma;
* Retrospective study: previously patients with hematological malignancies;
* Prospective study: 1) patients with clinical suspect of hematological malignancies which requires a diagnostic assessment using peripheral blood drawn, bone marrow aspirate/biopsy, lymph nodes biopsies or biopsies of tissues with metastatic involvement including liquor from rachicentesis, tissue aspirate etc. 2) patients with clinical suspect of relapsed/refractory onco-hematological disorder, which requires a diagnostic assessment using bone marrow aspirate/biopsy or biopsies of tissues with metastatic involvement including lymph nodes, liquor from rachicentesis, tissue aspirate etc. 3) patients that progress in blastic transformation from a chronic condition or suspect of relapsed/refractory hematological disease, which requires a diagnostic assessment using peripheral blood drawn, bone marrow aspirate/biopsy, lymph nodes biopsies or biopsies of tissues with metastatic involvement including liquor from rachicentesis, tissue aspirate etc;
* Written informed consent. Retrospective study: informed consent will be signed during the first follow-up visit.

Exclusion Criteria:

* Age \<1 year old
* Patients who are unable to provide informed consent prior to any procedure for any reason.

Where it's running

• University of Parma
  Parma, Pr, Italy Recruiting

Study contacts

• Study coordinator: Giovanni Roti, Associate Professor
• Email: giovanni.roti@unipr.it
• Phone: +39 0521 702200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Multi-omics testing for blood and bone marrow cancers

  This project will test a multi-omics lab approach on bone marrow, blood, biopsy and other fluid samples from people with suspected or known hematologic cancers to see if it can better characterize their disease.

  Recruiting Azienda Ospedaliero-Universitaria di Parma · Parma, PR · NCT07445438

• Comprehensive multi-omics and functional profiling to fully characterize tumors

  This project tests whether detailed multi-omics and functional testing of tumor samples can better characterize high-risk blood and solid cancers for patients at participating centers.

  Recruiting at 2 sites Azienda Ospedaliero-Universitaria di Parma · Palermo, Palermo and 1 other locations · NCT07403630

• Two-step ATG to prevent GVHD after myeloablative allogeneic stem cell transplant

  This study tests whether a two-step dosing of rabbit ATG added to tacrolimus and low-dose methotrexate can help prevent severe acute and chronic GVHD in adults 18–60 receiving myeloablative allogeneic peripheral blood stem cell transplants for leukemia, MDS, or myeloproliferative disorders.

  Recruiting Phase 2 University of Alabama at Birmingham · Birmingham, Alabama · NCT06315309

• Preventing Acute GVHD After Stem Cell Transplant

  This study is testing a new way to give a medication before and during stem cell transplants to see if it can help prevent a serious condition called acute GVHD in patients.

  Recruiting Phase 2 University of Alabama at Birmingham · Birmingham, Alabama · NCT06265584

• Transplanting umbilical cord blood from unrelated donors

  This study is testing different ways to prepare patients for umbilical cord blood stem cell transplants to see how safe and effective the procedure is for them.

  Recruiting University of Rochester · Rochester, New York · NCT03016806

• Menin inhibitors in pediatric relapsed or refractory acute leukemia

  This study looks at kids with relapsed or treatment-resistant acute leukemia who have specific genetic changes and are treated with menin inhibitors to see how they fare.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07898436

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.